AAV Vector Electroporation for Higher Virus Yield

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for producing adeno-associated virus (AAV) vectors face challenges in scalability and productivity, particularly for the treatment of systemic diseases, due to issues with chemical reagents like polyethyleneimine and the complexity of controlling plasmid and cell stirring, leading to low virus production efficiency and high costs.

Innovation Solution

A virus production method involving electroporation with specific conditions defined by the CNET product formula, including nucleic acid concentration, electric field strength, and pulse duration, which enhances virus production efficiency and capsid rate, especially using flow electroporation and suspension cells like HEK293, without the need for transfection reagents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If polyethyleneimine is used to neutralize plasmid DNA charge and introduce it into cells via endocytosis, then gene introduction can be achieved, but the process becomes complex and virus production efficiency decreases

Engineering Contradiction:
Improveease of gene introductionVSAvoidvirus production efficiency
Core Design Contradiction:
Ease of manufactureVSProductivity

Solution Approach 1:

The invention extracts and removes polyethyleneimine from the transfection process, replacing chemical reagent-based endocytosis with direct electroporation. This eliminates the complexity of controlling plasmid-polymer complex formation and stirring, while significantly improving virus production efficiency through direct physical introduction of nucleic acid into cells

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention replaces the chemical mechanism (polyethyleneimine-mediated endocytosis) with a physical mechanism (electroporation). By applying electric fields to create temporary pores in cell membranes, the method directly introduces nucleic acid without chemical reagents, simplifying the process and improving productivity

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If plasmid and cells are stirred for a long time to facilitate gene introduction, then introduction efficiency improves, but the process complexity and time requirements increase

Engineering Contradiction:
Improvegene introduction efficiencyVSAvoidstirring time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The invention uses periodic electric pulses instead of continuous stirring. The electroporation process applies short, intense electric pulses that create temporary pores in cell membranes, allowing rapid nucleic acid uptake without prolonged mechanical stirring. This periodic action achieves high introduction efficiency while dramatically reducing process time

Inventive Principle:
Principle #19Periodic action

Solution Approach 2:

The invention skips the lengthy stirring process required for chemical transfection by using electroporation. The electric field rapidly drives nucleic acid into cells through membrane pores within seconds, bypassing the need for prolonged mixing and incubation periods

Inventive Principle:
Principle #21Skipping (Rushing through)

3Productivity

If conventional electroporation methods are used without specific CNET product optimization, then virus production can be achieved, but the amount of virus production is insufficient for systemic disease treatment

Engineering Contradiction:
Improvevirus production amountVSAvoidsuitability for systemic disease treatment
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The invention optimizes electroporation parameters by controlling the CNET product (concentration × number of pulses × electric field strength × pulse duration). By adjusting these parameters to achieve a specific CNET product value, the method maximizes virus production yield, producing sufficient quantities for systemic disease treatment while maintaining high-quality viral vectors

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method significantly improves virus production capacity, increasing the full capsid rate and reducing production costs, making it suitable for large-scale production of AAV vectors for systemic disease treatments.

Implementation Method 1

electroporation, which makes use of cell membrane perforation by electric field application and the principle of electrophoresis

Methodology Applied
Scientific EffectElectroporation:

Implementation Method 2

the principle of electrophoresis

Methodology Applied
Scientific EffectElectrophoresis: Electrophoresis

Data Source

PatentEP4692359A1Virus production method
Publication Date: 2026.02.11 FUJIFILM CORP
  • EP4692359A1 patent drawingFigure 1~2
  • EP4692359A1 patent drawingFigure 3~4
  • EP4692359A1 patent drawingFigure 5~6

AI summary

An object of the present invention is to provide a virus production method capable of improving an amount of virus production. According to the present invention, there is provided a virus production method including a nucleic acid introduction step of introducing a nucleic acid into cells via electroporation to obtain cells into which the nucleic acid has been introduced; and a culture step of culturing the cells into which the nucleic acid has been introduced, in which a CNET product defined in the present specification in the electroporation is 1 × 104 or more and 1 × 107 or less.